Veracyte, Inc.
43.86USD
+1.4100 (+3.32%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 296.5M | 361.1M | 445.8M | 517.1M | 593.7M | 659.9M |
| Q1 | 67.8M | 82.4M | 96.8M | 114.5M | 139.1M | — |
| Q2 | 72.9M | 90.3M | 114.4M | 130.2M | 150.3M | — |
| Q3 | 75.6M | 90.1M | 115.9M | 131.9M | 147.1M | — |
| Q4 | 80.3M* | 98.2M* | 118.6M* | 140.6M* | 157.3M | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -.510 | -1.02 | .310 | .820 | 1.91 | 1.95 |
| Q1 | -.200 | -.110 | -.020 | .090 | .350 | — |
| Q2 | -.130 | -.120 | .070 | -.010 | .310 | — |
| Q3 | -.120 | -.410 | .190 | .240 | .413 | — |
| Q4 | -.054* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| -.389* |
| .065* |
| .511* |
| .449 |
| — |